According to recent reports, there has been a growing tendency for pharmaceutical companies to outsource analytical testing. Perhaps this is due to the complex nature of bringing new drugs to market and growing regulatory concerns in this area. Whatever the reason, it is reported that the market industry revenue in the context of outsourcing analytical testing is estimated to grow to $9.71 billion by 2025.
Despite claims that the population could potentially flatten out in future decades or even stop growing altogether, we do have a number of years before we get to that stage. As the population continues to increase until then, we are likely to see a natural rising demand for pharmaceuticals, biopharmaceuticals and biosimilars. In order to meet this rising demand, pharmaceutical companies will be expected to bring products to market quickly and efficiently. They will also be expected to increase their output of existing drugs – all while ensuring that products are meeting compliance standards.
Is Outsourcing the Right Choice?
Perhaps it is unsurprising then that some companies are looking to outsource this area. Some companies, whether they be large or small, might not have the necessary capital (labour, equipment and funding) to conduct in-house testing. As a result, this creates a demand for pharma companies to review suppliers that can provide such testing. The majority of analytical outsourcing will be in relation to bioanalytical testing (clinical and non-clinical), methods of development, and validation and stability testing. Any type of outsourcing that can help cut costs and bring a product from testing to development to sale should be undertaken. However, is this always an economically sound investment? Is there a way to conduct such analytical testing in-house, without needing to rely on third-party suppliers?
Raw Material Verification is one important type of test that needs to take place in the pharmaceutical environment. Traditionally, this has been time-consuming and costly as it involves a process of moving substances to a sampling booth (risking contamination), conducting the tests and then waiting for laboratory results. However, nowadays many other methods exist which can be conducted in-house, including handheld Raman analysis.
Progeny by Rigaku
Progeny by Rigaku brings this process to a whole other level. Its 1064 nm laser excitation means that it is now possible to test more materials than ever before. It is portable and handheld with an extensive onboard library. It also fits snugly in the palm of your hand – allowing on the spot and easy verification of a huge range of materials.
As more and more companies begin to outsource various operations that make economic sense to outsource, there will be a further rise in demand, quicker and more reliable results, and improved efficiency. However, when organisations are enabled to conduct at least some of this testing in-house, not only will the organisation benefit from lower costs and higher profit margins, but society too will benefit from lower price drugs and increased volume from improved efficiencies.